OBJECTIVE： To evaluate the safety of clinical application of bevacizumab， and to provide reference for rational and safe use of it. METHODS： Using “beifa dankang” “beifazhu dankang” “anweiting” “buliang fanying” “Avastin” “Bevacizumab” “ADR” as keywords， literatures about bevacizumab-induced ADR were retrieved from PubMed， Ovid， Web of Science， CJFD， VIP， Wanfang database from the establishment of database to Dec. 2015， all of which were collected and categorized by EndNote X7 software. Included literatures were analyzed by using Excel 2007 in respects of publication time and country， indications， organs/systems involved in ADR， clinical manifestations， etc. RESULTS： A total of 240 literatures were included. There were 199 original articles， 19 reviews and 22 case reports. When bevacizumba was used for malignant solid tumor， the common ADRs were mainly hypertension， hemorrhage， thromboembolism， proteinuria， which were consistent with package inserts of bevacizumba. But the common ADRs diarrhea and constipation as the package inserts described were not found in the included literatures. In addition， heart failure may be a severe ADR which was neglected. High dose was risk factor of hypertension； the location and type of a tumor were associated with hemorrhage； advanced age and history of thrombosis were the risk factors of thromboembolism. ADRs induced by super-indication use of bevacizumab for ocular neovascularization were corneal abrasion， crystalline lens injury， endophthalmitis， increased intraocular pressure， ablatio retinae， uveitis， etc. CONCLUSIONS： When applying bevacizumab， clinical physicians and pharmacists should rule out the high risk population and strengthen ADR monitoring， select suitable dose and course and deal with ADR properly.